- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - 2nd Quarter Results
AnnouncementREG - GlaxoSmithKline PLC - Sanofi and GSK agree UK doses of COVID-19 vaccine
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK receives positive CHMP opinion for Belamaf
AnnouncementREG - GlaxoSmithKline PLC - GSK and CureVac enter collaboration
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - FDA Panel Votes IN FAVOR of Belantamab mafodotin
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - GSK’s daprodustat gains first regulatory approval
AnnouncementREG - GlaxoSmithKline PLC - FDA Advisory Committee review belantamab mafodotin
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement